901 related articles for article (PubMed ID: 17363065)
1. Levosimendan: beyond its simple inotropic effect in heart failure.
Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
[TBL] [Abstract][Full Text] [Related]
2. A promising new inotrope: levosimendan.
Fotbolcu H; Duman D
Anadolu Kardiyol Derg; 2010 Apr; 10(2):176-82. PubMed ID: 20382619
[TBL] [Abstract][Full Text] [Related]
3. Levosimendan: dual mechanisms for acute heart failure...and beyond?
Ng TM; Akhter MW
Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
[TBL] [Abstract][Full Text] [Related]
4. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
Cleland JG; Nikitin N; McGowan J
Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
[TBL] [Abstract][Full Text] [Related]
5. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
6. The utility of levosimendan in the treatment of heart failure.
Lehtonen L; Põder P
Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
[TBL] [Abstract][Full Text] [Related]
7. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
Earl GL; Fitzpatrick JT
Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan: implications for clinicians.
McBride BF; White CM
J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
[TBL] [Abstract][Full Text] [Related]
9. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
Perrone SV; Kaplinsky EJ
Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan: a novel agent in heart failure.
Koumallos N; Antoniades C; Tousoulis D; Shirodaria C; Stefanadis C
Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):185-91. PubMed ID: 18221085
[TBL] [Abstract][Full Text] [Related]
12. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
Kota B; Prasad AS; Economides C; Singh BN
J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan: a new option in acute cardiac failure.
Holley AD; Ziegenfuss M
Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
[No Abstract] [Full Text] [Related]
14. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system.
Antoniades C; Antonopoulos AS; Tousoulis D; Bakogiannis C; Stefanadi E; Stefanadis C
Curr Drug Metab; 2009 Feb; 10(2):95-103. PubMed ID: 19275545
[TBL] [Abstract][Full Text] [Related]
15. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
Cavusoglu Y
Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
[TBL] [Abstract][Full Text] [Related]
16. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells.
Yokoshiki H; Katsube Y; Sunagawa M; Sperelakis N
J Pharmacol Exp Ther; 1997 Oct; 283(1):375-83. PubMed ID: 9336346
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan: current status and future prospects.
Archan S; Toller W
Curr Opin Anaesthesiol; 2008 Feb; 21(1):78-84. PubMed ID: 18195615
[TBL] [Abstract][Full Text] [Related]
18. Levosimendan: a new approach for the treatment of patients with severe heart failure. A brief summary based on a clinical case.
Morais J; Dias B; Pontes N
Rev Port Cardiol; 2003; 22(7-8):941-8. PubMed ID: 14587161
[TBL] [Abstract][Full Text] [Related]
19. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
Kivikko M; Lehtonen L
Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
[TBL] [Abstract][Full Text] [Related]
20. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording.
Despas F; Trouillet C; Franchitto N; Labrunee M; Galinier M; Senard JM; Pathak A
Acute Card Care; 2010 Mar; 12(1):25-30. PubMed ID: 19929264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
